Investing Strategies

March 28, 2016

Buy ($175)

Companies covered: AT&T Inc. (NYSE:T), Apple Inc. (NASDAQ:AAPL), CVS Health Corporation (NYSE:CVS), Target Corporation (NYSE:TGT), Walgreens Boots Alliance, Inc. (NASDAQ:WBA), W.W. Grainger, Inc. (NYSE:GWW), Hershey Company (The) (NYSE:HSY), Gilead Sciences, Inc. (NASDAQ:GILD), Arthur J. Gallagher & Co. (NYSE:AJG), Brown & Brown, Inc. (NYSE:BRO), GE Aerospace (General Electric Company) (NYSE:GE), ABAXIS, Inc. (NASDAQ:ABAX), Laboratory Corporation of America Holdings (NYSE:LH), Quest Diagnostics Incorporated (NYSE:DGX), Edwards Lifesciences Corporation (NYSE:EW), Valero Energy Corporation (NYSE:VLO), Ford Motor Company (NYSE:F), General Motors Company (NYSE:GM), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), FuelCell Energy, Inc. (NASDAQ:FCEL), Solazyme, Inc. (NASDAQ:SZYM), GlaxoSmithKline PLC (NYSE:GSK), Novartis AG (NYSE:NVS), Amgen Inc. (NASDAQ:AMGN), Merck & Company, Inc. (NYSE:MRK), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Unilever PLC (NYSE:UL), Archer-Daniels-Midland Company (NYSE:ADM), Popeyes Louisiana Kitchen, Inc. (NASDAQ:PLKI)

Health Care IT

March 11, 2016

Buy ($175)

Companies covered: GE Aerospace (General Electric Company) (NYSE:GE), McKesson Corporation (NYSE:MCK), Cerner Corporation (NASDAQ:CERN), Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), athenahealth, Inc. (NASDAQ:ATHN), IBM (International Business Machines Corp.) (NYSE:IBM), Premier, Inc. (NASDAQ:PINC), Siemens AG (OTCMKTS:SIEGY), Evolent Health Inc. (NYSE:EVH), WebMD Health Corp (NASDAQ:WBMD), Walgreens Boots Alliance, Inc. (NASDAQ:WBA), The Advisory Board Company (NASDAQ:ABCO), Cytori Therapeutics Inc (NASDAQ:CYTX), Authentidate Holding Corp. (OTCMKTS:ADAT), Health Insurance Innovations, Inc. (NASDAQ:HIIQ), Quality Systems, Inc. (NASDAQ:QSII)

Medical Devices

March 11, 2016

Buy ($175)

Companies covered: Medigus Ltd. (NASDAQ:MDGS), Profound Medical Corp. (CVE:PRN), iCAD, Inc. (NASDAQ:ICAD), EndoChoice Holdings, Inc. (NYSE:GI), NanoVibronix Inc. (NASDAQ:NAOV), Akers Biosciences Inc (NASDAQ:AKER), DexCom, Inc. (NASDAQ:DXCM), Nevro Corp. (NYSE:NVRO), ConforMIS Inc (NASDAQ:CFMS), Johnson & Johnson (NYSE:JNJ), Stryker Corporation (NYSE:SYK), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Smith & Nephew SNATS, Inc. (NYSE:SNN), Medtronic, Inc. (NYSE:MDT), St. Jude Medical, Inc. (NYSE:STJ), Boston Scientific Corporation (NYSE:BSX), Intuitive Surgical, Inc. (NASDAQ:ISRG), TransEnterix, Inc. (AMEX:TRXC), Alphabet Inc (NASDAQ:GOOG)

Medical Research, Diagnostic Substances & Life Science Tools

March 11, 2016

Buy ($175)

Companies covered: Fibrocell Science Inc (NASDAQ:FCSC), Affymetrix, Inc. (NASDAQ:AFFX), Bruker Corporation (NASDAQ:BRKR), Fluidigm Corporation (NASDAQ:FLDM), Illumina, Inc. (NASDAQ:ILMN), Pacific Biosciences of California, Inc. (NASDAQ:PACB), PerkinElmer, Inc. (NYSE:PKI), Waters Corporation (NYSE:WAT), Veracyte, Inc. (NASDAQ:VCYT), Rosetta Genomics Ltd. (NASDAQ:ROSG), TrovaGene, Inc. (NASDAQ:TROV), T2 Biosystems, Inc. (NASDAQ:TTOO), Thermo Fisher Scientific Inc (NYSE:TMO), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Agilent Technologies, Inc. (NYSE:A), Becton, Dickinson and Company (NYSE:BDX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Danaher Corporation (NYSE:DHR), Pall Corporation (NYSE:PLL), Bio-Techne Corp (NASDAQ:TECH), Medgenics, Inc. (NYSEMKT:MDGN), Spectral Medical Inc. (TSE:EDT), Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS), Cesca Therapeutics Inc. (NASDAQ:KOOL)